期刊文献+

Neoadjuvant chemoradiation is associated with decreased lymph node ratio in borderline resectable pancreatic cancer:A propensity score matched analysis

下载PDF
导出
摘要 Background:Lymph node ratio(LNR)and margin status have prognostic significance in pancreatic cancer.Herein we examined the pathologic and clinical outcomes in patients with borderline resectable pancreatic cancer(BRPC)following neoadjuvant therapy(NAT)and pancreaticoduodenectomy.Methods:Patients who underwent treatment between January 1,2012 and June 30,2017 were included.Sequential patients in the BRPC group were compared to a propensity score matched cohort of patients with radiographically resectable pancreatic cancer who underwent upfront surgical resection.The BRPC group was also compared to sequential patients with radiographically resectable pancreatic cancer who required vein resection(VR)during upfront surgery.Results:There were 50 patients in the BRPC group,50 patients in the matched control group,and 38 patients in the VR group.Negative margins(R0)were seen in 72%,64%,and 34%of the BRPC,control,and VR groups,respectively(P=0.521 for BRPC vs.control;P=0.002 for BRPC vs.VR),with 24%of the BRPC group requiring a vascular resection.Nodal stage was N0 in 64%,20%,and 18%of the BRPC,control,and VR groups,respectively(P<0.001 for BRPC vs.control or VR).When nodal status was stratified into four groups(N0,or LNR≤0.2,0.2–0.4,≥0.4),the BRPC group had a more favorable distribution(P<0.001).The median overall survival were 28.8,38.6,and 19.0 months for the BRPC,control,and VR groups,respectively(log-rank P=0.096).Conclusions:NAT in BRPC was associated with more R0 and N0 resections and lower LNR compared to patients undergoing upfront resection for resectable disease.
出处 《Hepatobiliary & Pancreatic Diseases International》 SCIE CAS CSCD 2021年第1期74-79,共6页 国际肝胆胰疾病杂志(英文版)
  • 相关文献

参考文献1

二级参考文献10

  • 1Brian A. Boone,Jennifer Steve,Alyssa M. Krasinskas,Amer H. Zureikat,Barry C. Lembersky,Michael K. Gibson,Ronald G. Stoller,Herbert J. Zeh,Nathan Bahary.Outcomes with FOLFIRINOX for borderline resectable and locally unresectable pancreatic cancer[J].J Surg Oncol.2013(4)
  • 2Matthew H. G. Katz,Robert Marsh,Joseph M. Herman,Qian Shi,Eric Collison,Alan P. Venook,Hedy L. Kindler,Steven R. Alberts,Philip Philip,Andrew M. Lowy,Peter W. T. Pisters,Mitchell C. Posner,Jordan D. Berlin,Syed A. Ahmad.Borderline Resectable Pancreatic Cancer: Need for Standardization and Methods for Optimal Clinical Trial Design[J].Annals of Surgical Oncology.2013(8)
  • 3Caroline S. Verbeke.Resection Margins in Pancreatic Cancer[J].Surgical Clinics of North America.2013(3)
  • 4Pavlos Papavasiliou,Yun Shin Chun,John P. Hoffman.How to Define and Manage Borderline Resectable Pancreatic Cancer[J].Surgical Clinics of North America.2013(3)
  • 5Gregory A. Coté,Jeffrey Smith,Stuart Sherman,Kimberly Kelly.Technologies for Imaging the Normal and Diseased Pancreas[J].Gastroenterology.2013(6)
  • 6Somnath Mukherjee,Christopher N Hurt,John Bridgewater,Stephen Falk,Sebastian Cummins,Harpreet Wasan,Tom Crosby,Catherine Jephcott,Rajarshi Roy,Ganesh Radhakrishna,Alec McDonald,Ruby Ray,George Joseph,John Staffurth,Ross A Abrams,Gareth Griffiths,Tim Maughan.Gemcitabine-based or capecitabine-based chemoradiotherapy for locally advanced pancreatic cancer (SCALOP): a multicentre, randomised, phase 2 trial[J].Lancet Oncology.2013(4)
  • 7F. Calvo,C. Guillen Ponce,M. Mu?oz Beltran,A. Sanjuanbenito Dehesa.Multidisciplinary management of locally advanced–borderline resectable adenocarcinoma of the head of the pancreas[J].Clinical and Translational Oncology.2013(3)
  • 8Krishna S. Gunturu,Xiaopan Yao,Xiangyu Cong,Jaykumar R. Thumar,Howard S. Hochster,Stacey M. Stein,Jill Lacy.FOLFIRINOX for locally advanced and metastatic pancreatic cancer: single institution retrospective review of efficacy and toxicity[J].Medical Oncology.2013(1)
  • 9Govindarajan Narayanan,Peter J. Hosein,Geetika Arora,Katuzka J. Barbery,Tatiana Froud,Alan S. Livingstone,Dido Franceschi,Caio M. Rocha Lima,Jose Yrizarry.Percutaneous Irreversible Electroporation for Downstaging and Control of Unresectable Pancreatic Adenocarcinoma[J].Journal of Vascular and Interventional Radiology.2012(12)
  • 10Robert C.G. Martin,Kelli McFarland,Susan Ellis,Vic Velanovich.Irreversible Electroporation Therapy in the Management of Locally Advanced Pancreatic Adenocarcinoma[J].Journal of the American College of Surgeons.2012(3)

共引文献10

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部